Two more analysts tracking Community Health Systems have formally reacted to the company's profit warning last week. Most notably, Ana Gupte at Leerink Partners has slashed her price target for the hospital owner to $33, less than half the $75 she had expected CHS to reach in the coming year. She now rates CHS at 'market perform' instead of 'outperform' and says, among other things, that there is little sign medical cost trends will reverse themselves soon.
Over at Robert W. Baird, veteran analyst Whit Mayo has lowered his CHS rating from 'outperform' to 'neutral.' Mayo's new target for the Franklin-based company is $32, which is 15 percent above where the stock (Ticker: CYH) was changing hands in early Tuesday trading.
Robert W. Baird analyst Richard Eastman has downgraded shares of Clarcor to ‘neutral’ from ‘outperform’ after the Franklin-based filtration products maker reported worse-than-expected third-quarter profits. Eastman also has cut to $53 his price target for Clarcor, which closed Thursday’s trading (Ticker: CLC) at $48.39.
Analysts at Robert W. Baird have taken their rating for Genesco down a notch to 'neutral' from 'outperform.' The firm now sees shares of the Nashville-based retailer of shoes and other apparel (Ticker: GCO) climbing to $76 from their current level of $71 and change. Year to date, the stock is off about 7 percent.
Analysts at Robert W. Baird have launched coverage of HealthStream shares with a 'neutral' rating and a price target of $27. That leaves less than 10 percent of upside from where the shares (Ticker: HSTM) are changing hands today. They're down about 15 percent year to date.
Kevin Reynolds at Wunderlich Securities has raised his price target for shares of Pinnacle Financial Partners to $40 from $37 after the bank holding company reported its Q2 numbers. Reynolds says investors shouldn't put too much stock in the earnings beat because of a smaller loan loss provision, but he nonetheless likes Pinnacle's long-term prospects. Pinnacle shares (Ticker: PNFP) closed Thursday trading at $36.05 and are up 11 percent so far in 2014.
At Robert W. Baird, analyst Richard Eastman has hiked his rating on Clarcor shares to 'outperform' from 'neutral,' citing better fundamentals, the benefit of recent acquisitions and a decent valuation. He sees Clarcor (Ticker: CLC), which closed Thursday at $60.46, climbing to $67 in the coming quarters.
Robert W. Baird analyst Whit Mayo upgraded his AmSurg rating Friday to 'outperform' from 'neutral.' Mayo also boosted his price target for the company to $55 from $44.
Shares of the ambulatory surgery company (Ticker: AMSG) were down nearly 10 percent last week, following news that the company is offering almost 10 million shares to finance its acquisition of Sheridan Healthcare. Year to date, shares are down slightly. However, they're up 28 percent in the last 12 months.
A couple of analysts following Tractor Supply said Thursday that investors shouldn't overreact to the company's so-so 2014 guidance, which initially pushed down its shares by more than 5 percent. At Robert W. Baird, Peter Benedict says the company's fundamentals are strong enough to endure and that this pullback has created a good buying opportunity. Wells Fargo's Matt Nemer, meanwhile, expects the relatively bad news to be quickly surpassed by strong January numbers.
Those comments appear to have helped Tractor Supply investors quickly find a bottom Thursday and climb from there. At about 1:40 p.m., the stock (Ticker: TSCO) was down just 2 percent on the day on volume that was on track to be the double the average.
POSTDATA: WARRANTY DEEDS